



# Undetectable bacterial bioburden in reprocessed single-use endoscopic biopsy forceps: A single-center cross-sectional study

**Carlos JMC  
Pangilinan JAN**

*Institute of Digestive and  
Liver Diseases  
St. Luke's Medical Center  
Quezon City, Philippines*

Correspondence:  
Dr. Jenna Marie C. Carlos at  
jenna.carlos@yahoo.com

Accepted for publication:  
December 2019

## Abstract

**Significance:** The increasing cost of endoscopic accessories has prompted the practice of reprocessing single-use devices (SUD) to allow reuse. Although some endoscopy centers have adopted reprocessing to minimize cost, studies on its safety and efficacy are either lacking or with conflicting results. The objective of this study is to demonstrate the effectiveness of reprocessing in eliminating bacterial bioburden in single-use endoscopic biopsy forceps. **Methods:** This is a cross-sectional study. Endoscopy forceps used in healthy patients were chosen by simple random sampling to undergo a standard reprocessing protocol. Forceps used in patients who are receiving antibiotics and with bacterial, viral or fungal infection were excluded. Included forceps were swabbed and cultured for any organism. Bioburden was measured in which the growth of a high-concern organism with  $\geq 1$  colony-forming units (CFU) or any other bacteria with  $\geq 10$  CFU was considered significant. **Results:** Twenty-four endoscopy forceps were included (12 from upper GI and 12 from lower GI endoscopy). No growth of any organism was recorded in all reprocessed forceps with a mean time of incubation of three days. There was zero bioburden. **Conclusion:** Reprocessed endoscopy forceps demonstrated no bacterial bioburden with the protocol used in this study. If adopted and standardized, reprocessing of SUDs may have positive implications in minimizing healthcare costs and increasing accessibility of needed accessories.

**Keywords:** cross-sectional study, reprocessing, single-use devices, single-use endoscopy forceps, bioburden

## Background

More than five million upper GI endoscopies and more than 12 million colonoscopies are performed annually in the United States. It is presumed that most if not all of these procedures will require diagnostic devices, such as biopsy forceps, to complete the procedure. However, since most available endoscopic accessories are manufactured as single-use only, great economic burden is placed on patients that may hinder their compliance to endoscopy.

Some endoscopy centers all over the world have developed their own protocols for the reprocessing of single-use devices (SUD). However, there is no universal guideline for reprocessing and the safety and efficacy of

re-use has not been firmly established. This study aims to demonstrate the safety of reprocessing of single-use endoscopic biopsy forceps.

The increasing healthcare cost and cost of instruments has prompted the application of reprocessing of medical devices, such as endoscopic devices, which are marketed for single-use. If found that such reprocessing is safe, then patients and healthcare companies will have a lighter burden in terms of costs.

The reuse of medical devices has been in place since the 1970s. Devices made of steel, glass or metal were usually sterilized or cleaned with a cleaning solution before use for the next patient. After the 1970s, however, with the advent of more complex designs of medical devices, manufacturers started to produce

single-use devices in order to prevent the harm induced with reuse, such as that of malfunction due to wear-and-tear.<sup>1</sup>

Reusable devices, as defined by the US Food and Drug Administration, are those devices that are reprocessed and reused on multiple patients. On the other hand, SUDs or disposable devices are intended for use on one patient during a single procedure.<sup>2</sup> Devices are classified by their risk of transmission of infection based on Spaulding's Classification. Critical devices are those that come in contact with blood or tissue, such as surgical forceps and scissors. Semi-critical devices are those that come in contact with intact mucus membranes, such as endoscopes. Non-critical devices are those that come in contact with unbroken skin, such as a stethoscope and blood pressure apparatus. The minimum required activation level for each classification is as follows: Critical devices would require sterilization, semi-critical devices would require high-level disinfection, and non-critical devices would require low-level to intermediate disinfection.<sup>3</sup> Biopsy forceps, which come into contact with gastric and colonic mucosa, are classified as critical devices.

Reprocessing includes disinfection, sterilization, cleaning, repackaging and re-labelling a medical device in order to be used again. The process can be done within the hospital or by outside reprocessing facilities (also called *third-party reproprocessors*). In 2002, a Medical Device User Fee and Modernization Act was passed in US Congress which required that reprocessing must follow the disinfection procedure and use the disinfection equipment of original manufacturers.<sup>4</sup> There is no such law in the rest of the world.

Infectious disease complications of endoscopic procedures are rare. There is a 0-8% chance of bacteremia from esophagogastroduodenoscopy (EGD) with biopsy. The highest rate of bacteremia is seen in EGD with esophageal dilation at 22.8%. Infection from endoscopic procedures is thought to occur due to entry of microbial flora into possible mucosal trauma or instrumentation during the procedure.<sup>5</sup>

Data on the safety and efficacy of reprocessed SUDs is scarce and conflicting. A study in a medical center in Alabama tested the safety of single-use endoscopic biopsy forceps and snares after submitting them for reprocessing by a licensed third-party reproprocessor. The results were unfavorable; demonstrating that 79% of

reprocessed devices collected were positive for significant microbial growth by day 10 of incubation.<sup>6</sup>

A pilot study conducted in 2017 by the Mayo Clinic in Massachusetts tested single-use endoscopic variceal band ligators for bioburden after reprocessing. It showed better results compared to the Alabama study in that 95% of the devices collected showed no microbial growth. This study concluded that reprocessing of single-use devices is safe and effective.<sup>7</sup>

The performance of a reprocessed device is difficult to measure. There are no guidelines to ensure how a device is assured of its quality and performance after reprocessing. Several studies have depended on the surgeon or endoscopist's opinion on the performance of the device. In a study in 2010, laparoscopic surgical trocars were found to have decreased performance after repeated reprocessing. Trocars were found to be faulty and less flexible in terms of adjustment and had to be replaced intra-operatively.<sup>8</sup> A Korean study in 2012 compared the efficacy of disposable and reprocessed endoscopic biopsy forceps. Forceps performance was graded based on size of bite, ease of opening and closing. They concluded that disposable forceps performed better than reused forceps.<sup>9</sup> However, the study had possible significant bias, since only one endoscopist and three nurses graded all forceps used in an arbitrary manner (on a scale of 1 to 5, with 5 being excellent) and none of them were blinded.

Another study using reusable versus disposable forceps in obtaining endoscopic samples from canine patients was done in a veterinary hospital in Edinburgh, United Kingdom. Quality of biopsy samples in this study was measured in terms of adequacy of sample, depth of the sample, number of crush artifacts, and villi number seen. The study was promising in that there was no difference in quality of biopsy samples using either forceps even after 10 to 15 uses.<sup>10</sup>

If proven to be safe and effective, reprocessing of SUDs will have significant impact on the healthcare system. It might mean significantly less financial burden to patients and endoscopy units. It might pave the way for the better regulation of reprocessing practices across health institutions. The objective of this study is to demonstrate the efficacy of reprocessing of single-use endoscopic devices, specifically in eliminating bacterial bioburden in reprocessed single-use endoscopic biopsy forceps.

## Methodology


### Inclusion and Exclusion Criteria

Biopsy forceps used and reprocessed in our institution's endoscopy unit were swabbed and cultured. Bioburden was measured based on the description of surveillance for bacterial contamination of duodenoscopes after reprocessing as described by the Centers for Disease Control and Prevention. Growth of gram-negative bacilli such as *Escherichia coli*, *Klebsiella pneumoniae* and other Enterobacteriaceae, *Pseudomonas aeruginosa*, *Staphylococcus*, and *Enterococcus* (which are considered "high-concern" organisms) of more than or equal to one CFU was considered to be a positive result. Growth of other types of bacteria not mentioned (considered as "low-concern" organisms) was also considered a positive result if more than or equal to 10 CFUs were found on culture.<sup>11</sup>

The study included reprocessed biopsy forceps used during endoscopy in healthy patients that have undergone the standard reprocessing protocol in our institution. Forceps used in patients who are receiving antibiotics during the endoscopic procedure and those who have known ongoing bacterial, viral or fungal infections were excluded.

Twenty-four biopsy forceps were used in the study; twelve each for upper GI and lower GI endoscopy

forceps. The sample size was calculated based on the proportion of reprocessed biopsy forceps with bacterial growth after a single use, assumed to be 79% (in the study by Hambrick, 2001). With a maximum allowable error of 20% and a probability of 90%, the sample size for each group was 12 for determination of bacterial growth in the upper and lower GI tract. Forceps were chosen at random. For every other endoscopy procedure done in a day, the biopsy forceps, if used during the procedure, was evaluated for inclusion in the study. This type of sampling was done until adequate sample size was reached. Nineteen upper GI endoscopy forceps were evaluated for inclusion into the study. Seven were excluded due to the following: three were used on patients who tested positive for the rapid urease test, two were used on patients undergoing antibiotic treatment, and two were used on patients with ongoing systemic infection (sepsis). For lower GI endoscopy, fifteen colonoscopy forceps were evaluated for inclusion. Three were excluded due to the following: one was used on a patient suspected to have infectious colitis; the second one was used on a patient with ongoing antibiotic treatment; and the third one was used on a patient suspected to have schistosomiasis. Twelve forceps for each group were then reprocessed and results were evaluated. This process is summarized in **Figure 1**.



**Figure 1.** Sampling and inclusion of endoscopy forceps

Selected biopsy forceps were reprocessed using the standard reprocessing protocol of the institution where this study was conducted. Forceps were soaked in Cidezyme®, an enzymatic detergent solution, for 20 minutes. The forceps were air-dried in a positive pressure room for 30 minutes and then sent for central sterilization to undergo Sterrad®, a sterilization procedure that uses low temperature gas plasma and peroxide.

After reprocessing, each biopsy forceps was swabbed from its handle to the tip using sterile technique. The swabbed specimens were sent for culture for any organism. Based on the reference on endoscope bioburden of the Centers of Disease Control and Prevention, a significant result is the detection of a high-concern organism: gram-negative bacilli with  $\geq 1$  CFU or any other bacteria with  $\geq 10$  CFUs. Bioburden was based on percentage of positive growth over the whole population.

### Ethical Considerations

The clinical protocol and all relevant documents were reviewed and approved by the St. Luke's Medical Center Research and Biotechnology Division and the Institutional Ethics Review Committee, who deemed the study presented no more than minimal risk to the subjects and a waiver of informed consent did not adversely affect the rights and welfare of the subjects. Patient confidentiality was ensured by anonymity of patient records. All study data were recorded and investigators were held accountable for the integrity of the data such as accuracy, completeness and legibility. The manner of disseminating and communicating the study results guaranteed the protection of the confidentiality of patient's data. Data for this study will be kept for a maximum of three years by the investigators. Once the study is concluded, all physical data such as data collection forms shall be shredded and electronic and digitized data shall be electronically deleted.

### Results

Characteristics of the biopsy forceps included in the study are summarized in **Table 1**. The most common indication for esophagogastroduodenoscopy was uninvestigated dyspepsia, while biopsy in the upper GI tract was mainly for rapid urease testing. The most

common indication for colonoscopy was lower GI bleeding, while biopsy in the lower GI tract was mainly for biopsy of polyps.

All 12 upper GI endoscopy forceps and all 12 lower GI endoscopy forceps did not show any growth of any organism at a mean time of three days of incubation. Culture results were re-examined at a maximum of 5 days and no still no growth was recorded at this time. No bioburden was noted with these results.

**Table 1.** Endoscopy and biopsy indications of study forceps included (n=24)

	Upper GI Endoscopy Forceps (n=12)	Lower GI Endoscopy Forceps (n=12)
<b>Indication for Endoscopy</b>		
Uninvestigated dyspepsia	9	N/A
Recurrent reflux	3	N/A
Lower GI bleeding	N/A	10
Screening	N/A	1
Constipation	N/A	1
<b>Indication for Biopsy</b>		
Polyp	2	12
Rapid urease test	10	N/A

### Discussion

#### *Rationale for Reprocessing*

There are several reasons why health care providers have started to reprocess single-use devices. The most obvious and strongest argument for reprocessing is cost. This is especially true in developing countries where the high cost of health care can limit proper medical management to patients. This is also true in resource-limited settings wherein new devices for each procedure cannot be regularly acquired. Cost of reprocessed biopsy forceps may be negotiated to a much lower price, which is a great concern to many Filipinos, of whom many still pay for health care out-of-pocket. For example, an economic analysis in Canada computed about 49% savings when reprocessing of SUDs was utilized.<sup>12</sup> In a French study in 2003, the cost per use of reprocessed endoscopic biopsy forceps was cut in half per use. In the French study, the mean number of uses was an average of 90 reuses per forceps.<sup>13</sup>

Environmental issues have also emerged in that the disposal of single-use devices contribute to the already growing medical waste. Reprocessing medical devices

can help in reducing this environmental burden. It would take about one US dollar to properly discard each pound of medical waste. In a 2013 article, a hospital in Boston estimated that 10,000 pounds of medical waste was avoided with reprocessing.<sup>14</sup> In actuality, many health care institutions around the world have already taken to reprocessing SUDs for the reasons stated above.

#### *Issues in Reprocessing*

The latest medical devices have been engineered in such complex ways in order to serve their medical purpose. The materials and parts of a device may be fragile and intricate so that it may only be used once for it to perform adequately. Manufacturers label a device as “single use” when they can only claim its safety and efficacy for only one use on one patient. After reprocessing, manufacturers are not liable for any adverse effects in terms of performance of the device.

The World Health Organization has also passed a memorandum citing additional concerns with use of reprocessed SUDs. Reprocessing may alter the device design and material which may affect function. Reprocessed SUDs may harbor infectious agents retained by cross-contamination which may not be adequately removed during reprocessing.<sup>2,4</sup>

Once a health center has decided to proceed with reprocessing of SUDs, certain procedures need to be in place in order to alleviate risks. The reprocessed device should be properly labeled, with forward and backward tracing in order to determine the reprocessing events and the performance of the device after reprocessing.

Issues on patient consent have also emerged with the use of reprocessed SUDs. It is argued that if proper reprocessing protocols are in place, then a patient’s consent to use a reprocessed SUD may not be needed. On the other hand, it has also been argued that hospitals may be violating the patient’s right to decide on the matter.<sup>15</sup> To date, there is no specific law that prohibits the reprocessing of SUDs, except in France, where it is illegal.

In the USA, the Medical Fee Act of 2002 regulates the reprocessing of SUDs and requires regular submission of data on reprocessed devices. In fact up to 30% of US hospitals report that they use reprocessed SUDs. Most other countries do not have such validation and regulation practices. In Canada, for example, each healthcare institution is given the independence to have

their own guidelines and policies on reprocessing as long as they follow the original disinfection procedure done by the original manufacturer. In the United Kingdom, reprocessing is discouraged due to possible legal consequences. On the other hand, in European countries such as Germany and Spain, up to 40-80% of hospitals reprocess SUDs. In the Middle East and in Asia, including the Philippines, there are no government regulations in place and most reprocessing is done within the same health care institution and conforms to each institution’s standard protocol on reprocessing.<sup>2,4,16</sup>

Some of these issues may be easily overcome in our country if a standardized reprocessing protocol is used and if a governing independent body will continuously monitor the quality of reprocessing in each endoscopy unit. Ethical considerations such as patient consent in the use of reprocessed forceps may be discussed as per each hospital’s ethical committee.

With the institutional reprocessing protocol used in this study, no bioburden was seen on SUDs after one reprocessed cycle.

#### **Conclusion**

The results of this study show that reprocessing endoscopic biopsy forceps efficiently eliminates bacterial bioburden after one cycle. However, data is still wanting on the presence of viral and/or fungal bioburden, and on bioburden after more than one reuse. Also, further studies need to prove whether or not reprocessing affects performance of these forceps.

#### **Conflict of Interest**

The authors declare no conflicts of interest.

#### **References**

1. American College of Obstetricians and Gynecologists. Committee Opinion on Reprocessed Single-Use Devices Number 537. *Obstet Gynecol.* 2012 October; 120(4):974-6.
2. United States Food and Drug Administration. Reprocessing and reuse of single-use devices: Review prioritization scheme. Published Feb 8, 2000. Retrieved on February 14, 2018, from [www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM073761.pdf](http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM073761.pdf).
3. Spaulding EH. Chemical disinfection of medical and surgical materials. In CA Lawrence & SS Block (Eds.), *Disinfection, sterilization and preservation*. Philadelphia: Lea & Febiger. 1968; pp. 517-531.
4. Mansur, JM. Reuse of single-use devices: Understanding risks and strategies for decision-making for health care

- organizations. A White Paper by Joint Commission International. 2017; Retrieved February 14, 2018, from [www.jointcommissioninternational.org](http://www.jointcommissioninternational.org).
5. Nelson D. Infectious disease complications of GI endoscopy. *Gastrointestinal Endoscopy*. 2003; 57 (4):546-556.
  6. Hambrick D. Reprocessing of single-use endoscopic biopsy forceps and snares: One hospital's study. *Gastroenterology Nursing*. 2001 May/June; volume 24 (3):112-115.
  7. Visordia K, Haseeb A, Hanada Y, Pennington KM, Clemens M, Pearce PJ, Tosh PK, Petersen BT, and Topazian MD. Reprocessing of single-use endoscopic variceal band ligation devices: a pilot study. *Endoscopy*. 2017; 49:1202-1208.
  8. Mues AC, Haramis G, Cazazza C. Prospective randomized single-blinded in vitro and ex vivo evaluation of new and reprocessed laparoscopic trocars. *J Am Coll Surg*. 2010 Dec; 211(6):738-43.
  9. Lim CH, Choi M, Kim WC, Ki JS, Cho YK, Park JM, Less IS, Kim SW, Choi KY, and Chung IS. Performance and cost of disposable biopsy forceps in upper gastrointestinal endoscopy: comparison with reusable biopsy forceps. *Clin Endosc*. 2012; 45:62-66.
  10. Cartwright JA. Evaluating quality and adequacy of gastrointestinal samples collected using reusable or disposable forceps. *Journal of Veterinary Internal Medicine*. 2016; volume 30, issue 4:1002-1007.
  11. Centers for Disease Control and Prevention. Interim protocol for healthcare facilities regarding surveillance for bacterial contamination of duodenoscopes after reprocessing. 2015 November; Retrieved February 14, 2018, from <https://www.cdc.gov/hai/settings/lab/lab-duodenoscope-culture-method.html>.
  12. Jacobs P, Polisen J, Hailey D, and Lafferty S. Economic analysis of reprocessing single-use medical devices: A systematic literature review. *Infect Control Hosp Epidemiol*. 2008 Apr; 29(4):297-301.
  13. Bourguignon C, Destrumelle AS, Koch S, Grumblat , Carayon P, Chopard C, and Woronoff-Lemsi MC. Disposable versus reusable biopsy forceps in GI endoscopy: A cost-minimization analysis. *Gastrointest Endosc*. 2003 Aug; 58(2):226-229.
  14. Lee J. Repositioning reprocessing. Published on July 6, 2013. Retrieved February 16, 2018, from [www.modernhealthcare.com/article/20130706/MAGAZINE/307069957](http://www.modernhealthcare.com/article/20130706/MAGAZINE/307069957).
  15. Collier R. The ethics of reusing single-use devices. *CMAJ*. 2011 August; 183(9):1245.
  16. United States Food and Drug Administration. Document on enforcement priorities for single-use devices reprocessed by third parties or hospitals. Issued on August 14, 2000. Retrieved on February 16, 2018, from [www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM107172.pdf](http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM107172.pdf).